news
Novel antiviral compound proposed as COVID-19 therapeutic
A molecule called BOLD-100, developed to fight cancer, has been suggested as a therapeutic to combat the COVID-19 coronavirus due to its antiviral properties.
List view / Grid view
Covid-19
news
FDA and BARDA to collaborate with Grifols on COVID-19 therapeutics
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.
article
Host pathways in coronavirus replication and COVID-19 pre-clinical drug target identification using proteomic and chemoinformatic analysis
The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains. Here, Joseph Steward highlights key findings of recent research.
news
Remdesivir most promising COVID-19 drug, say researchers
A review of potential COVID-19 therapeutics revealed that the most effective are likely to be those directly targeting SARS-CoV-2, such as remdesivir and tilarone.
article
The race to find a coronavirus treatment: are antibodies the answer?
At the beginning of March, US President Donald Trump pressed the pharmaceutical industry to “accelerate the development” of vaccines and therapies to contain the outbreak of the coronavirus pandemic. This article explores what is currently known about COVID-19 and potential treatments that are in the pipeline.
news
Collaboration initiated to develop COVID-19 immunotherapy
The University of Georgia and CEL-SCI Corporation have partnered to develop an immunotherapy to combat the COVID-19 coronavirus using the Ligand Antigen Epitope Presentation System (LEAPS) technology.
news
COVID-19 viral envelope simulation under development
Researchers are working to build a complete, all-atom model of the exterior of the coronavirus to aid in drug design.
article
Pooling research and development resources to tackle emerging threats
Here, Sheraz Gul highlights some encouraging displays of industry co-operation that aim to counter the global threat posed by COVID-19.
news
Map of COVID-19 and human protein interactions reveals drug targets
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
news
Chronic use of heart disease medications may increase the risk of severe COVID-19
A researcher has revealed that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may increase the risk of severe lung complications in COVID-19.
news
UK Consortium to monitor spread and behaviour of coronavirus
The UK government has invested £20 million into the COVID-19 Genomics UK Consortium, which will use whole genome sequencing to inform infection control measures and therapeutic developments.
article
Antibodies In-Depth Focus 2020
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
news
COVID-19 research hub: promoting scientific collaboration
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
news
Researchers to screen compound library for antiviral drugs to combat COVID-19
Scripps Research has announced it will screen over 14,000 compounds to see if any present significant activity against COVID-19, for use in a therapeutic.
news
Preliminary SARS-CoV-2 protease inhibitor shows efficacy in mice
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
